261 related articles for article (PubMed ID: 21963050)
1. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
[TBL] [Abstract][Full Text] [Related]
2. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
3. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
[TBL] [Abstract][Full Text] [Related]
4. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
Freedland SJ; Terris MK; Platz EA; Presti JC
Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
[TBL] [Abstract][Full Text] [Related]
5. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
10. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study.
De Nunzio C; Albisinni S; Freedland SJ; Miano L; Cindolo L; Finazzi Agrò E; Autorino R; De Sio M; Schips L; Tubaro A
Urol Oncol; 2013 Oct; 31(7):997-1002. PubMed ID: 21925906
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
13. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
[TBL] [Abstract][Full Text] [Related]
14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
15. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
16. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
19. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
20. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
